LNCD(SH:600739)2018-10-30 16:00Financial Performance - Operating revenue for the first nine months reached CNY 14,170,201,635.68, a 44.63% increase year-on-year[6] - Net profit attributable to shareholders decreased by 43.33% to CNY 698,601,790.81 compared to the same period last year[6] - Basic and diluted earnings per share dropped by 43.33% to CNY 0.4567[6] - The net profit from continuing operations for Q3 2018 was CNY 331,033,241, a decrease from CNY 413,621,508 in Q3 2017, representing a decline of approximately 19.9%[27] - The total profit for Q3 2018 was CNY 370,188,923, compared to CNY 456,039,367 in Q3 2017, marking a decline of around 18.8%[26] - The net profit attributable to the parent company was CNY 244,517,456 in Q3 2018, down from CNY 364,985,028 in Q3 2017, a decrease of approximately 33%[27] - The total comprehensive income for Q3 2018 was CNY 426,304,903, compared to CNY 561,877,661 in Q3 2017, reflecting a decrease of approximately 24%[27] Cash Flow - Net cash flow from operating activities was CNY 130,044,026.19, a significant recovery from a negative cash flow of CNY -86,469,089.18 in the previous year[6] - The net cash flow from operating activities for the first nine months of 2018 was -303,760,831.60 RMB, an improvement from -561,595,165.71 RMB in the same period last year[35] - Cash received from operating activities totaled 303,102,564.29 RMB, compared to 268,950,352.30 RMB in the previous year[35] - Cash paid for operating activities was 606,863,395.89 RMB, down from 830,545,518.01 RMB year-over-year[35] - The ending cash and cash equivalents balance as of the end of the reporting period was 893,946,186.05 RMB, up from 466,708,072.24 RMB at the end of the same period last year[36] Assets and Liabilities - Total assets increased by 2.75% to CNY 36,494,057,656.14 compared to the end of the previous year[6] - Total liabilities increased to CNY 14,714,065,441.32 from CNY 14,147,180,494.93, representing a rise of 4%[19] - Non-current liabilities totaled ¥4,844,544,787.59, up from ¥3,256,804,386.90, indicating a significant increase of 48.7%[19] - The company's short-term borrowings decreased by 33.57% to ¥4,086,068,760.57 from ¥6,151,358,708.00, mainly due to repayment of bank loans[9] - Long-term borrowings increased significantly by 604.08% to ¥690,000,000.00 from ¥98,000,000.00, reflecting a strategic shift in financing structure[9] Revenue and Costs - The total operating costs for Q3 2018 were CNY 4,912,462,779, up from CNY 3,335,510,902 in Q3 2017, indicating an increase of about 47.2%[26] - The total operating costs for the first nine months of 2018 were CNY 42,634,522.97, slightly up from CNY 42,405,473.61 in the previous year[28] - The company's financial expenses for the first nine months of 2018 were CNY 311,194,102.28, compared to CNY 276,389,168.98 in the same period last year, reflecting an increase in interest expenses[28] Shareholder Information - The total number of shareholders reached 71,980 by the end of the reporting period[7] - The largest shareholder, Liaoning Chengda Group Co., Ltd., holds 11.11% of the shares[7] Research and Development - Research and development expenses increased by 60.77% to ¥56,591,312.73 from ¥35,199,719.59, primarily due to increased investment in biopharmaceuticals[9] - Research and development expenses for Q3 2018 were CNY 13,849,894, slightly up from CNY 13,443,443 in Q3 2017, indicating a year-over-year increase of about 3%[26] Investment Income - The company reported a significant decrease in investment income, down 53.27% to ¥757,567,897.97 from ¥1,621,210,108.23, attributed to lower returns from joint ventures[9] - The company reported investment income of CNY 225,290,221.31 for Q3 2018, a decrease from CNY 384,326,075.63 in Q3 2017[28]